The recent appointment of Robert F. Kennedy Jr. as Secretary of Health by President-elect Donald Trump has sparked a wave of reactions in the pharmaceutical sector.

Kennedy, known for his skeptical positions on vaccines, has raised concerns among investors and public health experts, leading to a significant drop in the stocks of major pharmaceutical companies.

Robert F. Kennedy Jr., a lawyer and environmental activist, was chosen by Trump to lead the Department of Health and Human Services (HHS).

His appointment has been seen as a controversial move, given his long history of criticism towards vaccines and traditional health policies.

In fact, despite being portrayed by the press as an anti-vaxxer, Kennedy explained in a 2018 interview with Healthline that his commitment has always been to understand and verify the safety of vaccines, rather than opposing them outright.

However, immediately after the announcement of the appointment, the stocks of several pharmaceutical companies experienced a drastic decline.

MANAGER
Author: MANAGER

Views: 4

Lascia un commento